Analysis of domestic and foreign selling price changes in lorlatinib in 2025

Lorlatinib, as a third-generation ALK/ROS1 inhibitor, has gradually expanded its clinical application worldwide in recent years, and the price trend has also been affected by many factors. In 2025, in mainland China, lorlatinib has been included in the medical insurance catalog, and patients can obtain it through hospital pharmacies or designated drug catalogs. But even so, its original selling price is still high, with the price of a single box being about 10,000 to 20,000 yuan. The specific price after medical insurance reimbursement varies depending on the region and reimbursement ratio. Overall, domestic selling prices have declined in recent years, mainly due to the promotion of the medical insurance negotiation mechanism.

In the international market, the pricing of the original drug of lorlatinib shows a certain degree of differentiation. For example, the price of the original research version in the Turkish market is relatively low, about more than 7,000 yuan per box, which is highly cost-effective and attracts many overseas drug purchasers. In the Hong Kong market, the same original drug sells for about 30,000 yuan, with a large price gap. This is mainly due to factors such as the lack of unified local medical insurance negotiation prices, different tax systems, and a relatively free market pricing mechanism.

In addition to original drugs, there are also generic versions in many countries on the market, mainly from Laos and Bangladesh. These generic drugs are basically the same in terms of ingredients and bioequivalence, and the price is more affordable, generally more than 1,000 yuan per box. As more generic drugs enter the market, the price of lorlatinib has shown a slow downward trend globally, especially for patients with limited financial conditions. These generic drugs provide viable alternatives.

To sum up, 2025The price trend of lorlatinib at home and abroad shows a "dual-track" trend: the domestic original drug has gradually become accessible through medical insurance, and the price has declined; while in the international market, prices are uneven due to differences in local policies; the popularity of generic drugs has further lowered the threshold for patients to use the drug. In the future, as more generic drugs are approved and policy support is strengthened, lorlatinib is expected to achieve more reasonable pricing and wider accessibility globally.

Reference materials:https://www.drugs.com/